Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.

The Annual China Healthcare Industry Investment and Financing Honor List is jointly launched by CHC Medical Consulting and CITIC Securities, and is an authoritative ranking in the healthcare field from a third-party perspective. Since the release of the first list in 2018, the Honor List selection has become one of the important indicators for the development and investment and financing of China's medical and health industry. The release of the Honor List is not only a recognition and recognition of the contributors to the value of the healthcare industry, but also an encouragement and motivation for the entire industry, reflecting the positive values and positive energy within the industry.

Shengshi Taike was once again selected as one of the top 50 most influential medical and health enterprises in China this year. Despite facing challenges in the industry in the past two years, it has continued to achieve innovative results. At the beginning of last year, the company independently developed a new generation of highly selective DPP-4 inhibitor, Sengliptin (formerly known as Shenggliptin), and the NDA application was accepted by the National Medical Products Administration. Professor Ji Linong, an internationally renowned diabetes expert and the director of the Department of Endocrinology of Peking University People's Hospital, announced the data and results of the phase III clinical trial of Sengliptin. The data showed that compared with the similar drugs that have been marketed, the treatment effect of Sengliptin is expected to be the best hypoglycemic drug of its kind in terms of "quantity" and "half power". Even more valuable is that its safety further solves the common adverse reactions in products already on the market. At present, this product has entered the final review stage, and after its successful launch, it will provide more effective and safe optimal hypoglycemic programs for patients in China, a large country with diabetes. At the same time, the company has also carried out a comprehensive layout of oral drugs and derivative diseases around the global mainstream target of diabetes.

In the field of cancer, the company has already entered the clinical stage with four of its anti-cancer drugs under research, and two have completed the dual reporting between China and the United States, marking a solid step for the company's innovative drugs to go global. Among them, CGT-1881 is a CXCR4 targeted drug that has attracted global attention, used in the field of hematopoietic stem cell mobilization and other therapeutic fields. It is the only original small molecule oral CXCR4 antagonist in China, which can provide patients with better medication compliance. CXCR4 (chemokine receptor), as a popular target for global research and development, not only plays a key role in tumors, but also has close relationships with some immune diseases, genetic diseases, and viral diseases. At present, CGT-1881 is steadily advancing clinical trial research in healthy subjects, non Hodgkin's lymphoma or multiple myeloma patients.

Shengshi Taike was founded in Suzhou Industrial Park in 2010. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. With an integrated drug research and development technology platform and a diversified business perspective, the company has built a rich pipeline of innovative drugs, covering multiple disease fields such as hypoglycemic, anti-cancer, and autoimmune.